Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290054 | 0.91 | NPC1 (0.66) | NPC1RAB9AALDH1A1ALOX12GLA | |
| SCHEMBL7475623 | 0.91 | NPC1 (0.66) | NPC1RAB9AALDH1A1ALOX12GLA | |
| SCHEMBL2584410 | 0.91 | ALDH1A1 (0.65) | NPC1RAB9AALDH1A1ALOX12GLA | |
| SCHEMBL5126108 | 0.87 | NPC1 (0.54) | NPC1RAB9AALDH1A1ALOX12GLA | |
| SCHEMBL5126653 | 0.84 | SMN1; SMN2 (0.53) | NPC1RAB9AALDH1A1ALOX12GLA | |
| SCHEMBL1594519 | 0.84 | ALDH1A1 (0.56) | NPC1RAB9AALDH1A1ALOX12GLA | |
| SCHEMBL7474517 | 0.84 | RAB9A (0.65) | NPC1RAB9AALDH1A1ALOX12GLA | |
| SCHEMBL5161443 | 0.82 | NPC1 (0.87) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL5382549 | 0.80 | ACACB (0.56) | NPC1RAB9AHTTKDM4E | |
| SCHEMBL5530332 | 0.80 | ALDH1A1 (0.49) | NPC1RAB9AALDH1A1ALOX12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-7273880-B2 | Selective NPY (Y5) antagonists | H. LUNBECK A/S (DK) | 2007-09-25 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| EP-1183245-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2007-05-09 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-6989379-B1 | Selective NPY (Y5) antagonists | H. LUNDBICK A/S (DK) | 2006-01-24 | — | — | US | disclosed |
| EP-1194421-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2005-10-12 | — | — | EP | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-06-23 | — | — | US | disclosed |
| EP-1183245-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1194421-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1194421-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1183245-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6222040-B1 | FOR THERAPY OF EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-6218408-B1 | FOR THERAPY OF EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6214853-B1 | DIETETICS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-10 | — | — | US | disclosed |
| WO-2001002379-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000064880-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
| US-6124331-A | TREATING ABNORMAL FEEDING DISORDERS (OBESITY AND BULIMIA NERVOSA), SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | NPC1 1985/4885RAB9A 4151/4885ALDH1A1 4639/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | NPC1 1985/4885RAB9A 4151/4885ALDH1A1 4639/4885 |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | NPC1 1760/4885RAB9A 4038/4885ALDH1A1 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.